Sinovac Biotech (SVA) CBO Helen Yang reports 172,900 common shares

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD executive Yang Guang (Helen), the Chief Business Officer, has filed an initial ownership report. The Form 3 shows she directly holds 172,900 common shares of the company. This filing records her existing stake as an insider and does not reflect a new purchase or sale.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yang Guang (Helen)

(Last) (First) (Middle)

SEE REMARKS

(Street)

BEIJING 100020

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	172,900	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The full street address is 3rd Floor, Building 6, Sinovac Lifecity, West Road, Erbozi Industrial Park, Changping District. Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Helen Yang’s Form 3 filing show for SINOVAC BIOTECH LTD (SVA)?

The Form 3 filing shows Chief Business Officer Yang Guang (Helen) directly holds 172,900 common shares of SINOVAC BIOTECH LTD. This is an initial ownership report that records her existing insider stake rather than a new market transaction.

How many SINOVAC BIOTECH LTD (SVA) shares does Helen Yang report owning?

Helen Yang reports direct ownership of 172,900 common shares of SINOVAC BIOTECH LTD. This total is listed as shares held following the reported information and reflects her current insider position in the company’s common equity.

Does Helen Yang’s Form 3 for SINOVAC BIOTECH LTD (SVA) show a stock buy or sell?

No, the Form 3 does not show a stock buy or sell. It classifies the entry as a holding, with transaction direction marked as unknown, meaning it simply discloses Helen Yang’s existing 172,900-share position as an insider.

What type of security does Helen Yang hold in SINOVAC BIOTECH LTD (SVA)?

She holds common shares of SINOVAC BIOTECH LTD with a par value of $0.001 per share. The filing reports 172,900 of these common shares as directly owned, giving clarity on the nature of her equity stake.

Is Helen Yang’s ownership in SINOVAC BIOTECH LTD (SVA) direct or indirect?

The filing classifies Helen Yang’s stake as direct ownership. The ownership code is listed as “D” with no separate entity or trust indicated, meaning the 172,900 common shares are reported as held directly in her name.

What role does Helen Yang hold at SINOVAC BIOTECH LTD (SVA) in this Form 3?

In the Form 3, Helen Yang is identified as the Chief Business Officer of SINOVAC BIOTECH LTD. As an officer, she is required to report her equity holdings, which here are disclosed as 172,900 directly owned common shares.